MacroGenics - MGNX Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $14.00
  • Forecasted Upside: -22.82%
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
▲ +1.03 (6.02%)

This chart shows the closing price for MGNX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New MacroGenics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for MGNX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for MGNX

Analyst Price Target is $14.00
▼ -22.82% Downside Potential
This price target is based on 6 analysts offering 12 month price targets for MacroGenics in the last 3 months. The average price target is $14.00, with a high forecast of $17.00 and a low forecast of $12.00. The average price target represents a -22.82% upside from the last price of $18.14.

This chart shows the closing price for MGNX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Moderate Buy

The current consensus among 6 investment analysts is to moderate buy stock in MacroGenics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/14/2024HC WainwrightDowngradeBuy ➝ Neutral$12.00 ➝ $14.00Low
1/24/2024JMP SecuritiesBoost TargetMarket Outperform ➝ Market Outperform$10.00 ➝ $16.00Low
12/20/2023CitigroupUpgradeNeutral ➝ Buy$7.00 ➝ $13.00Low
11/27/2023Stifel NicolausReiterated RatingBuy ➝ Buy$17.00Low
11/13/2023HC WainwrightLower TargetBuy ➝ Buy$14.00 ➝ $12.00Low
11/7/2023GuggenheimUpgradeNeutral ➝ Buy$12.00Low
8/10/2023HC WainwrightReiterated RatingBuy ➝ Buy$14.00N/A
5/11/2023JMP SecuritiesBoost Target$8.00 ➝ $10.00Low
4/3/2023HC WainwrightReiterated RatingBuy$14.00Low
3/21/2023BTIG ResearchBoost TargetBuy$6.00 ➝ $12.00Low
3/20/2023CitigroupBoost Target$7.00 ➝ $8.00Low
3/20/2023HC WainwrightBoost Target$12.00 ➝ $14.00Low
3/17/2023GuggenheimReiterated RatingBuy ➝ NeutralLow
3/16/2023JMP SecuritiesReiterated RatingMarket Outperform$8.00Low
3/9/2023Stifel NicolausBoost Target$15.00 ➝ $17.00Low
1/19/2023JMP SecuritiesLower TargetMarket Outperform$18.00 ➝ $8.00Low
11/23/2022CitigroupDowngradeBuy ➝ Neutral$16.00 ➝ $7.00Low
11/22/2022GuggenheimUpgradeNeutral ➝ Buy$12.00Low
11/22/2022CowenDowngradeOutperform ➝ Market PerformLow
11/22/2022CowenDowngradeOutperform ➝ Market PerformLow
11/14/2022BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$5.70 ➝ $16.00Low
11/7/2022HC WainwrightBoost TargetBuy$11.00 ➝ $12.00Low
10/18/2022HC WainwrightBoost TargetBuy$10.00 ➝ $11.00N/A
9/12/2022HC WainwrightLower TargetBuy$35.00 ➝ $10.00Low
8/29/2022CitigroupBoost TargetBuy$13.00 ➝ $16.00Low
8/15/2022BarclaysLower Target$8.00N/A
8/9/2022SVB LeerinkLower TargetOutperform$15.00 ➝ $12.00Low
8/9/2022BarclaysLower TargetOverweight$18.00 ➝ $8.00Low
7/19/2022BTIG ResearchSet Target$6.00Low
7/18/2022Sumitomo Mitsui Financial GroupDowngradeOutperform ➝ Neutral$5.00Low
7/12/2022JMP SecuritiesLower TargetMarket Outperform$24.00 ➝ $20.00N/A
7/11/2022BTIG ResearchLower Target$6.00N/A
7/11/2022BMO Capital MarketsDowngradeOutperform ➝ Market Perform$31.00 ➝ $4.00N/A
5/4/2022GuggenheimDowngradeBuy ➝ NeutralHigh
5/4/2022HC WainwrightLower Target$41.00 ➝ $35.00High
2/28/2022CitigroupUpgradeNeutral ➝ Buy$23.00 ➝ $21.00High
2/25/2022BarclaysLower Target$35.00 ➝ $18.00High
2/25/2022SVB LeerinkLower TargetOutperform$40.00 ➝ $23.00High
2/11/2022BMO Capital MarketsInitiated CoverageOutperform$31.00High
2/4/2022Sumitomo Mitsui Financial GroupInitiated CoverageOutperform$40.00Low
11/17/2021GuggenheimInitiated CoverageBuy$30.00High
11/3/2021JMP SecuritiesLower TargetMarket Outperform$39.00 ➝ $38.00High
10/19/2021JMP SecuritiesInitiated CoverageOutperform$39.00Low
9/20/2021HC WainwrightReiterated RatingBuy$41.00Low
9/19/2021SVB LeerinkReiterated RatingBuyMedium
7/27/2021HC WainwrightReiterated RatingBuy$41.00Medium
6/17/2021HC WainwrightReiterated RatingBuyLow
6/16/2021BTIG ResearchInitiated CoverageBuyMedium
6/7/2021WedbushLower TargetOutperform$39.00 ➝ $34.00High
4/30/2021SVB LeerinkBoost TargetOutperform$37.00 ➝ $40.00High
4/30/2021HC WainwrightBoost TargetBuy$36.00 ➝ $41.00High
4/26/2021Morgan StanleyBoost TargetUnderweight$16.00 ➝ $17.00N/A
4/19/2021Morgan StanleyBoost TargetUnderweight$15.00 ➝ $16.00Medium
3/12/2021BarclaysUpgradeUnderweight ➝ Overweight$14.00 ➝ $40.00High
3/4/2021Morgan StanleyBoost TargetUnderweight$14.00 ➝ $15.00N/A
2/26/2021Morgan StanleyBoost TargetUnderweight$14.00 ➝ $15.00High
12/22/2020HC WainwrightReiterated RatingBuy$36.00Low
12/17/2020BarclaysBoost TargetUnderweight$8.00 ➝ $14.00High
11/13/2020Morgan StanleyBoost TargetUnderweight$13.00 ➝ $14.00Low
11/5/2020SVB LeerinkLower TargetOutperform$38.00 ➝ $37.00High
10/13/2020Morgan StanleyBoost TargetUnderweight$12.00 ➝ $13.00Low
9/21/2020SVB LeerinkBoost TargetOutperform$35.00 ➝ $38.00High
8/3/2020CitigroupDowngradeBuy ➝ Neutral$25.00 ➝ $26.00High
7/31/2020Morgan StanleyBoost TargetUnderweight$11.00 ➝ $12.00High
7/31/2020HC WainwrightReiterated RatingBuy$40.00High
7/15/2020Morgan StanleyBoost TargetUnderweight$6.00 ➝ $11.00Low
6/2/2020CitigroupBoost Target$15.00 ➝ $25.00Low
6/1/2020GuggenheimUpgradeNeutral ➝ BuyLow
5/29/2020SVB LeerinkBoost TargetOutperform$15.00 ➝ $27.00Medium
5/29/2020Stifel NicolausBoost TargetBuy$21.00 ➝ $36.00High
5/28/2020BTIG ResearchBoost TargetBuy$23.00 ➝ $35.00High
5/26/2020HC WainwrightBoost TargetBuy$22.00 ➝ $40.00High
5/17/2020NomuraReiterated RatingBuy$50.00Low
5/14/2020WedbushBoost TargetOutperform$16.00 ➝ $28.00Medium
5/12/2020Credit Suisse GroupBoost TargetOutperform$13.00 ➝ $30.00High
5/6/2020WedbushReiterated RatingOutperformHigh
5/6/2020Credit Suisse GroupLower TargetOutperform$17.00 ➝ $13.00High
5/6/2020SVB LeerinkLower TargetOutperform$16.00 ➝ $15.00High
5/6/2020HC WainwrightBoost TargetBuy$18.00 ➝ $22.00High
3/4/2020BarclaysInitiated CoverageUnderweight$8.00Medium
3/2/2020Credit Suisse GroupLower TargetOutperform$26.00 ➝ $17.00Low
2/26/2020HC WainwrightReiterated RatingBuy$18.00High
2/26/2020Stifel NicolausLower TargetBuy$21.00 ➝ $20.00High
2/26/2020CitigroupLower TargetBuy$18.00 ➝ $15.00High
1/21/2020WedbushBoost TargetOutperform$14.00 ➝ $16.00High
12/20/2019HC WainwrightReiterated RatingBuy$18.00High
12/18/2019Cantor FitzgeraldInitiated CoverageOverweight$17.00Medium
12/12/2019BTIG ResearchReiterated RatingBuy ➝ Positive$23.00High
12/12/2019Nomura SecuritiesReiterated RatingBuy$50.00High
12/10/2019HC WainwrightReiterated RatingBuy$18.00High
12/10/2019CowenReiterated RatingBuyN/A
11/21/2019Morgan StanleyDowngradeEqual ➝ Equal Weight$17.00 ➝ $6.00High
11/20/2019GuggenheimInitiated CoverageHoldHigh
11/7/2019CitigroupLower TargetBuy$39.00 ➝ $18.00Low
10/23/2019HC WainwrightLower TargetBuy$39.00 ➝ $18.00High
10/23/2019SVB LeerinkLower TargetOutperform$26.00 ➝ $18.00High
10/23/2019WedbushLower TargetOutperform$23.00 ➝ $14.00High
8/1/2019Stifel NicolausLower TargetBuy$29.00 ➝ $25.00High
7/18/2019WedbushReiterated RatingOutperform$27.00Low
6/5/2019Morgan StanleySet TargetHold$19.00Low
6/5/2019Stifel NicolausLower TargetBuy$36.00 ➝ $29.00Low
6/5/2019WedbushReiterated RatingOutperform$26.00 ➝ $27.00High
6/5/2019CowenReiterated RatingBuyHigh
5/3/2019WedbushUpgradeNeutral ➝ Outperform$26.00Low
5/2/2019HC WainwrightReiterated RatingBuy$39.00High
5/2/2019CowenReiterated RatingBuyHigh
4/17/2019Credit Suisse GroupInitiated CoverageOutperform$29.00High
4/12/2019GuggenheimInitiated CoverageNeutralMedium
4/4/2019HC WainwrightReiterated RatingBuy$39.00Medium
(Data available from 2/24/2019 forward)

News Sentiment Rating

0.64 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
  • 6 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 7 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 1 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions

Current Sentiment

  • 8 very positive mentions
  • 12 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
MacroGenics logo
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3;Retifanlimab, an monoclonal antibody used for cancer therapeutics; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
Read More

Today's Range

Now: $18.14
Low: $17.13
High: $18.19

50 Day Range

MA: $13.00
Low: $8.68
High: $18.30

52 Week Range

Now: $18.14
Low: $4.29
High: $18.85


1,033,003 shs

Average Volume

1,333,365 shs

Market Capitalization

$1.13 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of MacroGenics?

The following sell-side analysts have issued stock ratings on MacroGenics in the last twelve months: BTIG Research, Citigroup Inc., Guggenheim, HC Wainwright, JMP Securities, Stifel Nicolaus,, and TheStreet.
View the latest analyst ratings for MGNX.

What is the current price target for MacroGenics?

6 Wall Street analysts have set twelve-month price targets for MacroGenics in the last year. Their average twelve-month price target is $14.00, suggesting a possible downside of 22.8%. Stifel Nicolaus has the highest price target set, predicting MGNX will reach $17.00 in the next twelve months. Guggenheim has the lowest price target set, forecasting a price of $12.00 for MacroGenics in the next year.
View the latest price targets for MGNX.

What is the current consensus analyst rating for MacroGenics?

MacroGenics currently has 1 hold rating and 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for MGNX.

What other companies compete with MacroGenics?

How do I contact MacroGenics' investor relations team?

MacroGenics' physical mailing address is 9704 MEDICAL CENTER DRIVE, Rockville MD, 20850. The biopharmaceutical company's listed phone number is (301) 251-5172 and its investor relations email address is [email protected]. The official website for MacroGenics is Learn More about contacing MacroGenics investor relations.